Nektar to apply royalty windfall toward paying off debt

Nektar Therapeutics Inc. will use its $124 million windfall from the sale of its royalty interest in two drugs to help pay off a $215 million note due in September.
In a Securities and Exchange Commission filing Wednesday, the San Francisco-based drug developer (NASDAQ: NKTR) said it also is pursuing other “non-dilutive financing alternatives,” including the sale of other royalty interests, to pay off the convertible subordinated note.